252 related articles for article (PubMed ID: 35379802)
1. Multilayered control of splicing regulatory networks by DAP3 leads to widespread alternative splicing changes in cancer.
Han J; An O; Ren X; Song Y; Tang SJ; Shen H; Ke X; Ng VHE; Tay DJT; Tan HQ; Kappei D; Yang H; Chen L
Nat Commun; 2022 Apr; 13(1):1793. PubMed ID: 35379802
[TBL] [Abstract][Full Text] [Related]
2. Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT.
Vadlamudi Y; Dey DK; Kang SC
Curr Cancer Drug Targets; 2020; 20(9):654-665. PubMed ID: 32564755
[TBL] [Abstract][Full Text] [Related]
3. Alternative Splicing Outcomes Across an RNA-Binding Protein Concentration Gradient.
Ellis JA; Hale MA; Cleary JD; Wang ET; Andrew Berglund J
J Mol Biol; 2023 Aug; 435(15):168156. PubMed ID: 37230319
[TBL] [Abstract][Full Text] [Related]
4. Mutational landscape of RNA-binding proteins in human cancers.
Neelamraju Y; Gonzalez-Perez A; Bhat-Nakshatri P; Nakshatri H; Janga SC
RNA Biol; 2018 Jan; 15(1):115-129. PubMed ID: 29023197
[TBL] [Abstract][Full Text] [Related]
5. TF-RBP-AS Triplet Analysis Reveals the Mechanisms of Aberrant Alternative Splicing Events in Kidney Cancer: Implications for Their Possible Clinical Use as Prognostic and Therapeutic Biomarkers.
He M; Hu F
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445498
[TBL] [Abstract][Full Text] [Related]
6. Alternative splicing and cancer: a systematic review.
Zhang Y; Qian J; Gu C; Yang Y
Signal Transduct Target Ther; 2021 Feb; 6(1):78. PubMed ID: 33623018
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of splicing in cancer.
Lee SC; Abdel-Wahab O
Nat Med; 2016 Sep; 22(9):976-86. PubMed ID: 27603132
[TBL] [Abstract][Full Text] [Related]
8. Long Non-Coding RNA Expression Levels Modulate Cell-Type-Specific Splicing Patterns by Altering Their Interaction Landscape with RNA-Binding Proteins.
Porto FW; Daulatabad SV; Janga SC
Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31390792
[TBL] [Abstract][Full Text] [Related]
9. PCBP1 regulates the transcription and alternative splicing of metastasis‑related genes and pathways in hepatocellular carcinoma.
Huang S; Luo K; Jiang L; Zhang XD; Lv YH; Li RF
Sci Rep; 2021 Dec; 11(1):23356. PubMed ID: 34857818
[TBL] [Abstract][Full Text] [Related]
10. RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing.
Maurin M; Ranjouri M; Megino-Luque C; Newberg JY; Du D; Martin K; Miner RE; Prater MS; Wee DKB; Centeno B; Pruett-Miller SM; Stewart P; Fleming JB; Yu X; Bravo-Cordero JJ; Guccione E; Black MA; Mann KM
Nat Commun; 2023 Dec; 14(1):8444. PubMed ID: 38114498
[TBL] [Abstract][Full Text] [Related]
11. RBFOX2 alters splicing outcome in distinct binding modes with multiple protein partners.
Zhou D; Couture S; Scott MS; Abou Elela S
Nucleic Acids Res; 2021 Aug; 49(14):8370-8383. PubMed ID: 34244793
[TBL] [Abstract][Full Text] [Related]
12. Aberrant RNA splicing and therapeutic opportunities in cancers.
Yamauchi H; Nishimura K; Yoshimi A
Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550
[TBL] [Abstract][Full Text] [Related]
13. RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing.
Dvinge H; Guenthoer J; Porter PL; Bradley RK
Genome Res; 2019 Oct; 29(10):1591-1604. PubMed ID: 31434678
[TBL] [Abstract][Full Text] [Related]
14. Expression of Death Associated Proteins DAP1 and DAP3 in Human Pancreatic Cancer.
Sui L; Ye L; Sanders AJ; Yang Y; Hao C; Hargest R; Jiang WG
Anticancer Res; 2021 May; 41(5):2357-2362. PubMed ID: 33952460
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis reveals the prognostic value and functions of splicing factors implicated in hepatocellular carcinoma.
Wang Y; Yang F; Shang J; He H; Yang Q
Sci Rep; 2021 Jul; 11(1):15175. PubMed ID: 34312475
[TBL] [Abstract][Full Text] [Related]
16. Splicing factor poly(rC)-binding protein 1 is a novel and distinctive tumor suppressor.
Guo J; Jia R
J Cell Physiol; 2018 Jan; 234(1):33-41. PubMed ID: 30132844
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the aberrant splicing of MAP3K7 induced by cancer-associated SF3B1 mutation.
Li Z; Zhao B; Shi Y; Liang Y; Qian R; Wan Y
J Biochem; 2021 Sep; 170(1):69-77. PubMed ID: 33751071
[TBL] [Abstract][Full Text] [Related]
18. A Genetic Screen for Pre-mRNA Splicing Mutants of
Kanno T; Lin WD; Fu JL; Chang CL; Matzke AJM; Matzke M
Genetics; 2017 Dec; 207(4):1347-1359. PubMed ID: 28971960
[TBL] [Abstract][Full Text] [Related]
19. Novel insights into clear cell renal cell carcinoma prognosis by comprehensive characterization of aberrant alternative splicing signature: a study based on large-scale sequencing data.
Zhang D; Zhang W; Sun R; Huang Z
Bioengineered; 2021 Dec; 12(1):1091-1110. PubMed ID: 33783315
[TBL] [Abstract][Full Text] [Related]
20. The RNA-binding protein QKI suppresses cancer-associated aberrant splicing.
Zong FY; Fu X; Wei WJ; Luo YG; Heiner M; Cao LJ; Fang Z; Fang R; Lu D; Ji H; Hui J
PLoS Genet; 2014 Apr; 10(4):e1004289. PubMed ID: 24722255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
